Synagis intramuscular injection 50mg, from AstraZeneca, contains palivizumab (genetical recombination) and is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients. The standard is 50mg 0.5mL 1 bottle, YJ code 6250404A1020.
Synagis intramuscular injection 50mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →